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ABSTRACT
Susceptibility surveillance investigations have demonstrated an increased incidence of ESBL-producing
Gram-negative bacilli. Case cohort studies have suggested clinical relevance associated with ESBL-
producing Enterobacteriaciae infection. Yet, current laboratory reporting guidelines classify a large
percentage of these organisms in the susceptible category. The regulatory agencies Clinical Laboratory
Standards Institute (formly NCCLS) and EUCAST, which oversee these guidelines are in the process of
re-evaluating the appropriateness of the current classiﬁcation system. Pharmacokinetic and pharma-
codynamic studies examine the relationship between drug exposure (pharmacokinetics), antibiotic
potency (MIC), and treatment efﬁcacy. PK/PD studies and analyses have been useful in demonstrating
the relevance of increasingly less susceptible pathogens and speciﬁc emerging resistance mechanisms.
Recent investigations have examined the impact of ESBL-producing Gram-negative bacilli relative to
advanced generation cephalosporin pharmacokinetics. Animal model studies suggest that the
pharmacodynamic target associated with efﬁcacy in treatment of ESBL-producing organisms is the
same as that in therapy against non-ESBL-producing bacteria (50% T > MIC). Simulation of human
pharmacokinetics can predict the likelihood of achieving this PD target with speciﬁc cephalosporin
dosing regimens. In general, the exposure from usual regimens of the advanced generation
cephalosporins would not be anticipated to achieve the PD target for many of the organisms currently
classiﬁed as susceptible. PK/PD analyses should be useful in re-evaluating current susceptibility
breakpoints for ESBL-producing organisms and for optimising drug and regimen choice in treatment of
these infections.
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INTRODUCTION
Numerous multicentre studies have demonstra-
ted the importance of Gram-negative bacilli as a
cause of nosocomial infection [1–4]. More recent
surveillance databases have shown a continued
rise in rates of antimicrobial resistance among
these species. The great majority of resistance to
b-lactam antibiotics is due to the production of
hydrolysing b-lactamase enzymes. A multitude of
different enzymes have been identiﬁed over the
past decade [5,6]. The most recently identiﬁed
classes of b-lactamase have a broad b-lactam
spectrum that encompasses many broad-spec-
trum penicillins and cephalosporins. These en-
zymes have been termed extended-spectrum b-
lactamases (ESBLs). Current laboratory detection
methods fail to identify and classify many of these
organisms as resistant [7]. A number of recent
case series have suggested poor patient outcomes
after infection with ESBL-producing organisms
[8–10]. Despite these reports, factors related to the
importance of laboratory detection and classiﬁca-
tion of these pathogens remain controversial.
The ﬁeld of antimicrobial pharmacokinetics
and pharmacodynamics examines the relation-
ship between antimicrobial pharmacokinetics, the
MIC for an organism, and outcome [11]. These
analyses have been useful for determining the
impact of emerging resistance. Recent pharmaco-
kinetic ⁄pharmacodynamic (PK ⁄PD) studies have
addressed the importance of antibiotic resistance
due to ESBL-producing organisms. The results
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should be helpful in the development of suscep-
tibility breakpoints and for optimising dosing
regimens with currently available antibiotics.
EPIDEMIOLOGY OF
ESBL-PRODUCING ORGANISMS
The incidence of nosocomial infections with
Gram-negative pathogens has remained relatively
constant at 25–60%, depending upon the speciﬁc
study considered [3,4]. For example, Hoban et al.
examined the occurrence of pathogens respon-
sible for nosocomial pneumonia from 30 centres
in North America, and reported that 45% of cases
were due to Gram-negative bacilli among more
than 2700 patients [12]. The most common single
species involved was Pseudomonas aeruginosa, and
the most common family was Enterobacteriaceae
(20%) in this cohort. Among the Enterobacteria-
ceae, large global surveillance studies have iden-
tiﬁed reduced susceptibility to b-lactam
antibiotics. The largest of these investigations,
from the SENTRY programme, reported the
susceptibility of more than 18 000 strains in North
America, Latin America, Europe, and Asia [12–
16]. Among these strains, 5–50% had MICs of
ceftazidime and ceftriaxone equal to or greater
than 2 mg ⁄L. The percentages of strains exhibit-
ing these elevated MICs were greatest for Ente-
robacter spp. and lowest for Escherichia coli (E. coli
5–12%, Klebsiella spp. 9–19%, Serratia spp. 24–
50%). Resistance rates were highest in Latin
America and Asia. Of these organisms, 50–80%
were ESBL producers. Similar organism distribu-
tion and susceptibility proﬁles have been
observed in other surveillance series [17–19].
DETECTION AND CLASSIFICATION
OF ESBL-PRODUCING ORGANISMS
The Clinical Laboratory Standards Institute (CLSI,
formerly NCCLS) has considered the relevance of
these pathogens and published a clinical laborat-
ory screening method for detection of ESBL-
producing Enterobacteriaceae [7]. The screening
is based upon identiﬁcation of organisms depend-
ent upon ceftazidime, ceftriaxone, cefotaxime or
aztreonam MICs greater than or equal to 2 mg ⁄L
or cefpodoxime MICs greater than or equal to
8 mg ⁄L. Conﬁrmation of ESBL production is
based upon the effect of a concomitant b-lacta-
mase inhibitor, clavulanic acid. The presence of
an ESBL-producing organism is deﬁned as an
eight-fold or more reduction in the MIC with the
addition of the inhibitor.
According to the current CLSI classiﬁcation,
many of these organisms would fall within the
susceptible category. Organisms with MICs less
than or equal to 8 mg ⁄L for each of the advanced-
generation cephalosporins, ceftriaxone, cefotaxi-
me, and cefepime, are presently reported as
susceptible, with the resistance classiﬁcation
beginning with organism MICs of 64 mg ⁄L. Thus,
many ESBL-producing organisms are currently
considered to be within the susceptible category.
The appropriateness of these breakpoints is cur-
rently the topic of investigation and debate.
CLINICAL OUTCOME ASSOCIATED
WITH INFECTION DUE TO
ESBL-PRODUCING ORGANISMS
Investigation of the clinical relevance of infection
with ESBL-producing organisms has been limited
to case series. While the increased incidence of
these organisms has been repeatedly observed,
prior study of emerging pathogens has shown
that it is difﬁcult to accrue enough of these
patients in prospective multicentre treatment
and outcome studies to determine their impact
[20,21].
However, there has been an accumulation of
both retrospective and prospective investigations
describing poor treatment outcomes associated
with these ESBL-producing strains [8–10,22,23].
These studies are geographically diverse and
include a large number of patients with bacterae-
mia. For example, Patterson et al. identiﬁed 32
patients with bacteraemia due to ESBL-producing
organisms, more than two-thirds of whom failed
therapy despite treatment with drugs to which
the organisms were reportedly susceptible [9].
It is possible to extract data from ﬁve of these
series that provide a means to examine the impact
of the antibiotic monotherapy, ESBL production
and the MIC for an organism on outcome. From
the several hundred patients with ESBL infec-
tions, 42 cases provide the level of detail neces-
sary for this exercise (Table 1). Among these
patients infected with either an ESBL-producing
E. coli strain or Klebsiella pneumoniae, more than
60% had advanced-generation cephalosporin
MICs greater than or equal to 2 mg ⁄L. Treatment
failure was described in half of the patients. As
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the MIC for the infecting organism increases from
1 mg ⁄L, to 2 mg ⁄L, to 4 mg ⁄L and to 8 mg ⁄L,
there is a stepwise reduction in treatment success,
which falls from more than 80% with MICs of
1 mg ⁄L or less to 67% with MICs of 2 mg ⁄L, to
only 11% in patients infected with organisms for
which the MICs are 8 mg ⁄L. Despite the small
number of patients, the relationship between MIC
and outcome is clear. These data suggest that
current susceptibility and resistance categories
should be re-evaluated.
PHARMACOKINETICS ⁄
PHARMACODYNAMICS:
OPTIMISATION OF ANTIMICROBIAL
THERAPY
The ﬁeld of pharmacokinetics and pharmacody-
namics provides tools which can be helpful in
determining the relevance of these pathogens and
optimising the therapeutic approach to patients
[11]. PK ⁄PD analyses consider the relationship
between drug exposure, the antibiotic potency or
the MIC, and treatment efﬁcacy. Speciﬁc PK
values are utilised in describing the drug expo-
sure. Furthermore, the exposures are considered
relative to the potency of the drug or MIC of the
infecting pathogen. These PK values (Fig. 1)
include the peak level in serum in relation to the
MIC, the total amount of drug or area under the
concentration curve relative to the MIC, and the
amount of time for which the drug levels remain
above the MIC of the organism. The PD compo-
nent of the analysis examines the relationship
between these PK values and outcome.
PK ⁄PD studies and analyses have been under-
taken with most antibiotic drug classes currently
in use [11,24]. Three PD patterns have been
demonstrated from these studies. The PD charac-
teristics of drugs of the b-lactam class include
time-dependent killing and rapid organism recov-
ery when antibiotic concentrations fall below the
MIC of the organism. These drugs achieve peak
killing rates at relatively low multiples of MIC.
Higher drug concentrations do not kill pathogens
more rapidly. The efﬁcacy of drugs with these
characteristics is dependent on the amount of
time for which the serum drug concentration
exceeds the MIC of the agent [11,25]. Therefore,
the goal of the dosing regimen is to optimise the
duration of drug exposure.
Studies with b-lactams against organisms with
widely varying MICs have demonstrated that
successful treatment outcome is associated with
dosing regimens in which drug levels remain
above the MIC for approximately one-half of the
dosing interval or there is a percentage time
above MIC of 50% (%T > MIC) [11,25]. For
example, if b-lactam X is administered twice-
daily, serum levels would need to remain higher
than the MIC for at least 6 h.
The PK ⁄PD characterisation of antimicrobial
agents is most commonly undertaken using ani-
mal infection models [11,24,26]. The animal model
allows the study of a wide spectrum of drug
exposures with many organisms with different
MIC values, including those with reduced sus-
ceptibility and with deﬁned resistance mecha-
nisms. The results from these extensive in-vivo
experiments provide an estimate of the optimal
amount of drug relative to MIC that is required
for effect. This drug exposure is termed the PD
target. The PD target identiﬁed in animal model
studies can often be analysed relative to treatment
efﬁcacy in clinical trials [27–29].
The infection model most commonly utilised in
these studies is the mouse thigh infection model
[11,24,26]. The animals are rendered neutropenic
to allow the organisms to grow. Bacteria are
injected into the thigh, and animals are then
treated with a wide variety of antibiotic regimens.
Table 1. Clinical outcome in 42 patients with ESBL-pro-
ducing Klebsiella spp. or E. coli bacteraemia and treated
with cephalosporin monotherapy
Outcome MIC £ 1 mg ⁄L MIC 2 mg ⁄L MIC 4 mg ⁄L MIC 8 mg ⁄L
Success 81% 67% 27% 11%
Failure 19% 33% 73% 89%
Time (hours)
Co
nc
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n
MIC
Parameters of Interest:
Cmax (Peak)
Time > MIC
Area under the 
concentration curve
Time > MIC
Cmax/MIC ratio
AUC/MIC ratio
Fig. 1. Relationship between pharmacokinetic parameters
(Cmax, AUC and time of concentration) in relation to the
MIC.
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Antibiotic PK studies are undertaken and treat-
ment efﬁcacy is determined microbiologically at
the end of therapy at 24 h by plating dilutions of
thigh homogenates and enumerating viable bur-
den based upon plate counts. For some treatment
groups, therapy is continued for 5 days with a
survival endpoint. One can then examine the
impact of dose level on efﬁcacy and, using non-
linear regression analysis, calculate the dose level
needed to achieve any number of endpoints, such
as the static dose or the exposure associated with
no growth of organism over the treatment period.
Similarly, one can estimate the dose or drug
exposure needed to kill organisms to a certain
degree (e.g., 1 log reduction) or have some
percentage of maximal efﬁcacy (e.g., 80%).
Fig. 2 illustrates an example of data output
from this type of study. For these studies, differ-
ent groups of mice were infected with strains of
Steptococcus pneumoniae exhibiting varying levels
of susceptibility to penicillins and cephalosporins
[11,24]. Animals were then treated according to
one of several b-lactam regimens, with dose level
and administration frequency being varied. Treat-
ment efﬁcacy was then considered, relative to
PK ⁄PD values based upon drug pharmacokinet-
ics in the animals. In this example, animals were
treated for 5 days and survival was observed
throughout the treatment period. Each of the
dosing regimens in this case was represented by
the %T > MIC PD values, which have been
shown to be important in describing PD efﬁcacy
for drugs of the b-lactam class. Maximal survival
in these studies was observed when the b-lactam
regimens produced %T > MIC values ranging
from 40% to 50% of the dosing interval. Thus, the
PK ⁄PD target identiﬁed from these analyses is a
%T > MIC of 40–50%.
The number of clinical data sets that provide
pharmacokinetics, MICs for organisms, and out-
come, thus allowing this type of PD analysis, is
small. One study that provided this depth of
information concerned acute otitis media and
bacterial sinusitis [28]. The design of these studies
includes initial microbiological diagnosis based
upon middle ear or sinus puncture, with organ-
ism recovery for subsequent susceptibility testing.
Following antibiotic therapy, a second sampling
is used to determine whether bacteriological
eradication has been achieved. PD analysis con-
cerns antibiotic pharmacokinetics in relation to
the MIC and eradication of the organism from the
site of infection. Fig. 2 shows the results of
analysis of this type of study, with penicillins
and cephalosporins used in patients with bacter-
ial infection at one of these upper respiratory sites
[24]. The relationship between the %T > MIC of
the b-lactams and bacteriological eradication was
strong. Maximal bacteriological eradication of
organisms from the site of infection was related
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Fig. 2. Left panel: Relationship between b-lactam percentage time above MIC and mortality in a Streptococcus pneumoniae
murine infection model. Hollow symbols represent data with cephalosporins. Solid symbols represent data with penicillin.
Right panel: Relationship between b-lactam percentage time above MIC and bacteriological eradication in acute otitis
media and sinusitis. Hollow circles represent data with Haemophilus inﬂuenzae in otitis media. Hollow squares represent
data with H. inﬂuenzae in sinsusitis. Solid circles represent data with penicillin-susceptible S. pneumoniae in otitis media.
Solid squares represent data with penicillin-susceptible S. pneumoniae in sinusitis. Grey circles represent data with
penicillin-intermediate and -resistant S. pneumoniae in otitis media.
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to therapy with dosing regimens that produced a
%T > MIC of 40–50%. Remarkably, the PK ⁄PD
relationships observed in patients were very
similar to those in the animal model PD studies.
MONTE CARLO SIMULATION AND
PHARMACODYNAMIC
PREDICTIONS
Important sources of variation in these analyses
include both the distribution of MICs and the
pharmacokinetics in patients. For example,
among a large group of patients, use of antibiotic
X in some may result in drug concentrations
sufﬁcient for treatment efﬁcacy, while in others
the drug exposure may be inadequate. A statis-
tical methodology termed ‘Monte Carlo simula-
tion’ has been developed and recently used to
account for this type of variation in antibiotic
therapy [29,30]. Such analysis simulates PK vari-
ation in more than 10 000 patients in a single
study. The PK simulation can then be considered
relative to a PD target, such as the %T > MIC of
50% for b-lactams. This powerful simulation tool
enables investigators to predict the likelihood that
a particular antibiotic dosing regimen will achieve
a PD target against organisms with varying MICs
[29]. The highest MIC for which a dosing regimen
would be predicted to achieve the target for the
majority of the time (e.g., 95%) may then be
designated the MIC value above which organisms
are considered to be ‘resistant’ [30].
Both animal model pharmacodynamics and
analysis of clinical data sets can then be used in
these analyses for predicting therapeutic out-
come and for designing dosing regimens to
optimise treatment. Similarly, the pharmacoki-
netics of commonly used dosing regimens can be
considered relative to the MICs of common
pathogens to determine the highest MIC for
which the drug would be expected to be effect-
ive based upon the identiﬁed PD target. In this
manner, pharmacodynamics can be considered
by regulatory agencies in the development of
susceptibility breakpoints to be used by clinical
microbiology laboratories to categorise organ-
isms as susceptible or resistant. Indeed, this type
of data has been used by the CLSI and EUCAST
for the development of S. pneumoniae breakpoints
for b-lactams [7]. However, this type of analysis
has not been considered for all drugs and all
bacterial species, including organisms that pro-
duce ESBLs.
PHARMACOKINETICS ⁄
PHARMACODYNAMICS AND
ESBL-PRODUCING ORGANISMS
Similar animal model pharmacodynamic studies
have recently been undertaken to examine the
impact of ESBL production on treatment outcome
[31–33]. The PD target investigation was under-
taken using the mouse thigh infection model.
Animals were infected with one of a large number
of Gram-negative bacilli with widely varying
susceptibilities to the advanced-generation ce-
phalosporins (cefotaxime, ceftriaxone, ceftazi-
dime and cefepime). The E. coli, Klebsiella spp.,
Enterobacter spp. and Serratia spp. were chosen to
include drug-susceptible organisms and those
resistant, due to both ESBL production and other
well-characterised mechanisms (e.g., AmpC,
OXA1, OXA2, TEM1). Among the ESBL-produ-
cing strains, numerous different ESBL enzyme
types were represented (TEM3, TEM7, TEM12,
TEM26, SHV2, SHV4, SHV5, SHV7, CTXM2,
CTXM3). Following infection, animals received
four to six dose levels of either cefotaxime,
ceftriaxone, ceftazidime or cefepime, which were
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Fig. 3. Relationship between cephalosporin percentage
time above MIC and microbiological efﬁcacy against
Enterobacteriaciae in a murine thigh infection model.
Hollow symbols represent data with ESBL-producing
organisms. Solid symbols represents data with non-ESBL-
producing organisms. The dashed horizontal line repre-
sents the burden of organisms at the start of therapy. The
vertical dashed line represent the %T > MIC target asso-
ciated with a net static effect.
14 Clinical Microbiology and Infection, Volume 11 Supplement 6, 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11 (Suppl. 6), 10–17
administered every 6 h for 24 h. Analyses con-
sidered the burden of organisms in thighs of mice
relative to the drug exposure, in this case the
%T > MIC for the cephalosporin dosing regi-
mens. Fig. 3 shows the relationship between
efﬁcacy and the %T > MIC in therapy against
Enterobacteriaceae producing ESBLs (hollow
symbols) as well as those that did not produce
these enzymes (solid symbols). The dashed hori-
zontal lines represent the organism burden in the
thighs of mice at the start of therapy. Data points
above the line represent growth despite therapy,
points below the line represent organism killing,
and points on the line represent no growth or a
static effect over the treatment period. The regi-
mens examined produced a wide spectrum of
%T > MIC values, from dose levels that never
reached the MIC, to those that were above the
MIC for most or all of the dosing interval. The
exposure–response relationship intercepts the
start of therapy burden (net static effect) at a
%T > MIC value of approximately 40–50%, and
maximal efﬁcacy was observed at a%T > MIC of
60%. The %T > MIC response relationships were
identical in therapy against both groups of organ-
isms, suggesting that ESBL production did not
impact on the amount of drug necessary for
efﬁcacy. The PD analyses demonstrate that ESBL
production did not provide predictive informa-
tion beyond the MIC alone. The %T > MIC PD
target associated with cephalosporin efﬁcacy
against ESBL-producing organisms was similar
to that in other studies with other cephalosporins
and bacterial species [11].
MONTE CARLO SIMULATION AND
ESBL-PRODUCING ORGANISMS
The %T > MIC target identiﬁed in these animal
model studies can then be considered relative to
MIC distribution from surveillance studies and
human PK simulation using Monte Carlo simula-
tion. These simulations take into account a variety
of dose levels and dosing intervals. For example,
Dudley and Ambrose recently undertook simula-
tion of a ceftriaxone 2-g once-daily regimen
relative to %T > MIC targets and MIC distribu-
tion [7,30] (Table 2). If one considers a 50%
T > MIC target, the likelihood of the regimen
producing this ceftriaxone exposure or achieving
this target was nearly 100% for organisms with
MICs less than or equal to 2 mg ⁄L. However, the
likelihood of attainment fell below 60% with
organism MICs only a single dilution higher at
4 mg ⁄L. At the current susceptibility breakpoint
of 8 mg ⁄L, the likelihood of target attainment is
close to zero. Simulation with other cephalospo-
rins, as well as consideration of additional dose
levels and dosing intervals, has been performed
(Table 3). These analyses suggest that the likeli-
hood of treatment success based upon the current
breakpoints is low for many of the common
advanced-generation cephalosporin regimens.
However, for some drugs, regimens that include
both dose escalation and more frequent adminis-
tration can improve the likelihood of target
attainment and perhaps optimisation of therapy.
For example, if cefepime is administered as a 2-g
dose every 8 h, the PK simulations would predict
a high probability of target attainment against
organisms with MICs as high as 16 mg ⁄L.
If one considers the small ESBL clinical data set
presented in Table 1, it is perhaps not surprising
that, despite organisms being classiﬁed as ‘sus-
ceptible’, success with cephalosporin monothera-
py was uncommon in patients infected with these
organisms with MICs of 2, 4 and 8 mg ⁄L.
These data analyses have been presented to
both the CLSI and EUCAST for consideration in
the development of susceptibility breakpoints for
ESBL-producing bacteria.
Table 2. Monte Carlo simulation of ceftriaxone: percent-
age of 10 000 patients attaining indicated pharmacokinet-
ic ⁄pharmacodynamic exposure target
%T > MIC with 2 g every 24 h
40% 50% 60% 70%
0.5 100 100 100 100
1 100 100 100 99
2 100 99 93 74
4 87 58 25 6
8 8 1 0 0
16 0 0 0 0
Table 3. Pharmacokinetic ⁄pharmacodynamic considera-
tions in susceptibility breakpoint determination
Drug
NCCLS
breakpointa
(mg ⁄L)
Usual
regimen
% Attainment
at NCCLS
PK ⁄PD
breakpointa
(mg ⁄L)
Cefotaxime 8 ⁄ 16–32 ⁄ 64 1 g every 8 h 3 1 ⁄ 2 ⁄ 4
Ceftriaxone 8 ⁄ 16–32 ⁄ 64 1 g every 24 h 0 1 ⁄ 2 ⁄ 4
2 g every 24 h 1 2 ⁄ 4 ⁄ 8
Cefepime 8 ⁄ 16–32 ⁄ 64 1 g every 12 h 36 4 ⁄ 8 ⁄ 16
2 g every 12 h 91 8 ⁄ 16 ⁄ 32
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CONCLUSIONS
In an era of emerging resistant pathogens, epide-
miological studies rarely provide sufﬁcient and
timely data to demonstrate the relevance of these
pathogens. More importantly, clinical treatment
trials most often do not include enough patients
infected with these pathogens to allow the deter-
mination of optimal antimicrobial therapy. Thus,
the ﬁeld of pharmacokinetics and pharmacody-
namics can be useful in this context in deﬁning
the relevance of these organisms. More import-
antly, these studies can help in the design of
optimal therapeutic regimens and are likely to
become increasingly important in the develop-
ment of susceptibility breakpoint guidelines.
REFERENCES
1. Colodner R. Extended-spectrum beta-lactamases: a chal-
lenge for clinical microbiologists and infection control
specialists. Am J Infect Control 2005; 33(2): 104–107.
2. Anonymous. National Nosocomial Infections Surveillance
(NNIS) System report, data summary from January 1990–
May 1999, issued June 1999. Am J Infect Control 1999; 27:
520–532.
3. Safdar N, Maki DG. The commonality of risk factors for
nosocomial colonization and infection with antimicrobial-
resistant Staphylococcus aureus, enterococcus, gram-neg-
ative bacilli, Clostridium difﬁcile, and Candida. Ann Intern
Med 2004; 136(11): 834–844.
4. Fridkin SK, Steward CD, Edwards JR et al. Surveillance of
antimicrobial use and antimicrobial resistance in United
States hospitals: project ICARE phase 2. Project Intensive
Care Antimicrobial Resistance Epidemiology (ICARE)
hospitals. Clin Infect Dis 1999; 29(2): 245–252.
5. Bradford PA. Extended-spectrum beta-lactamases in the
21st century: characterization, epidemiology, and detec-
tion of this important resistance threat. Clin Microbiol Rev
2001; 14(4): 933–951.
6. Jacoby GA, Munoz-Price LS. The new beta-lactamases.
N Engl J Med 2005; 352(4): 380–391.
7. National Committee for Clinical Laboratory Standards.
Document M100-S14. Wayne, PA: NCCLS, 2004.
8. Kang CI, Kim SH, Park WB et al. Bloodstream infections
due to extended-spectrum beta-lactamase-producing
Escherichia coli and Klebsiella pneumoniae: risk factors for
mortality and treatment outcome, with special emphasis
on antimicrobial therapy. Antimicrob Agents Chemother
2004; 8(12): 4574–4581.
9. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of
cephalosporin treatment for serious infections due to
apparently susceptible organisms producing extended-
spectrum beta-lactamases: implications for the clinical
microbiology laboratory. J Clin Microbiol 2001; 39: 2206–
2212.
10. Wong-Beringer A, Hindler J, Loeloff M et al. Molecular
correlation for the treatment outcomes in bloodstream
infections caused by Escherichia coli and Klebsiella pneu-
moniae with reduced susceptibility to ceftazidime. Clin
Infect Dis 2002; 34(2): 135–146.
11. Craig W. Pharmacokinetic ⁄pharmacodynamic parameters:
rationale for antibacterial dosing of mice and men. Clin
Infect Dis 1998; 26: 1–12.
12. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN.
Pathogen of occurrence and susceptibility patterns asso-
ciated with pneumonia in hospitalized patients in North
America: results of the SENTRY Antimicrobial Surveil-
lance Study (2000). Diagn Microbiol Infect Dis 2003; 45(4):
279–285.
13. Bell JM, Turnidge JD, Jones RN, SENTRY Asia-Paciﬁc
Participants. Prevalence of extended-spectrum beta-lacta-
mase-producing Enterobacter cloacae in the Asia-Paciﬁc
region: results from the SENTRY Antimicrobial Surveil-
lance Program, 1998 to 2001. Antimicrob Agents Chemother
2003; 47(12): 3989–3993.
14. Gales AC, Sader H, Jones RN. Respiratory tract pathogens
isolated from patients hospitalized with suspected pneu-
monia in Latin America: frequency of occurrence and
antimicrobial susceptibility proﬁle: results from the SEN-
TRY Antimicrobial Surveillance Program (1997–2000).
Diagn Microbiol Infect Dis 2002; 44(3): 301–311.
15. DiPersio JR, Deshpande LM, Biedenbach DJ et al. Evolu-
tion and dissemination of extended-spectrum beta-lacta-
mase-producing Klebsiella pneumoniae: epidemiology
and molecular report from the SENTRY Antimicrobial
Surveillance Program (1997–2003). Diagn Microbiol Infect
Dis 2005; 51(1): 1–7.
16. Jones RN, Biedenbach DJ, Gales AC. Sustained activity
and spectrum of selected extended-spectrum beta-lactams
(carbapenems and cefepime) against Enterobacter spp.
and ESBL-producing Klebsiella spp.: report from the
SENTRY antimicrobial surveillance program (USA, 1997–
2000). Int J Antimicrob Agents 2003; 21(1): 1–7.
17. Nijssen S, Florijn A, Bonten MJ, Schmitz FJ, Verhoef J, Fluit
AC. Beta-lactam susceptibilities and prevalence of ESBL-
producing isolates among more than 5000 European En-
terobacteriaceae isolates. Int J Antimicrob Agents 2004;
24(6): 585–591.
18. Paterson DL, Rossi F, Baquero F et al. In vitro suscepti-
bilities of aerobic and facultative Gram-negative bacilli
isolated from patients with intra-abdominal infections
worldwide: the 2003 Study for Monitoring Antimicrobial
Resistance Trends (SMART). J Antimicrob Chemother 2005;
55: 965–973.
19. Bouchillon SK, Johnson BM, Hoban DJ et al. Determining
incidence of extended spectrum beta-lactamase producing
Enterobacteriaceae, vancomycin-resistant Enterococcus
faecium and methicillin-resistant Staphylococcus aureus in
38 centres from 17 countries: the PEARLS study 2001–2002
Int J Antimicrob Agents 2004; 24(2): 119–124.
20. Pallares R, Linares J, Vadillo M et al. Resistance to peni-
cillin and cephalosporin and mortality from severe pneu-
mococcal pneumonia in Barcelona, Spain. N Engl J Med
1995; 333(8): 474–480.
21. Feikin DR, Schuchat A, Kolczak M et al. Mortality from
invasive pneumococcal pneumonia in the era of antibiotic
resistance, 1995–1997. Am J Public Health 2000; 90(2): 223–
229.
22. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by
extended-spectrum beta-lactamase-producing Escherichia
16 Clinical Microbiology and Infection, Volume 11 Supplement 6, 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11 (Suppl. 6), 10–17
coli and Klebsiella pneumoniae in children: epidemiology
and clinical outcome. Antimicrob Agents Chemother 2002;
46(5): 1481–1491.
23. Bhavani SM, Jones RN, Ambrose PG, Mutnick AM, Sader
HS, Fritsche TR. Experience with ESBL producing
Enterobacteriaciae treated with carbapenems compared to
other beta lactams. In: 44th Interscience Conference of
Antimicrobial Agents and Chemotherapy, Washington
DC: American Society for Microbiology, 2004; 361.
24. Andes D, Craig WA. Animal model pharmacokinetics and
pharmacodynamics: a critical review. Int J Antimicrob
Agents 2002; 19: 261–268.
25. Andes D, Craig WA. In vivo activities of amoxicillin and
amoxicillin ⁄ clavulanate against Streptococcus pneumoni-
ae: application to breakpoint determinations. Antimicrob
Agents Chemother 1998; 42: 2375–2379.
26. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic
dose–effect relations at several dosing intervals in murine
pneumonitis and thigh-infection models. J Infect Dis 1989;
159(2): 281–292.
27. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics–
pharmacodynamics of cefepime and piperacillin–tazobac-
tam against Escherichia coli and Klebsiella pneumoniae
strains producing extended-spectrum beta-lactamases: re-
port from the ARREST program. Antimicrob Agents Chem-
other 2003; 47(5): 1643–1646.
28. Craig WA, Andes D. Pharmacokinetics and pharmacody-
namics of antibiotics in otitis media. Pediatr Infect Dis J
1996; 15: 944–948.
29. Drusano GL, Preston SL, Hardalo C et al. Use of preclinical
data for selection of a phase II ⁄ III dose for everninomicin
and identiﬁcation of a preclinical MIC breakpoint. Anti-
microb Agents Chemother 2001; 45: 13–22.
30. Dudley MN, Ambrose PG. Pharmacodynamics in the
study of drug resistance and establishing in vitro suscep-
tibility breakpoints: ready for prime time. Curr Opin
Microbiol 2000; 3: 515–521.
31. Andes D, Jacoby G, Craig W. Impact of extended-spec-
trum beta-lactamase production in K. pneumoniae on
activity of four beta-lactams in an animal infection model
[abstract]. In: 35th Interscience Conference on Antimicrobial
Agents and Chemotherapy, San Francisco, CA. Washington,
DC: American Society for Microbiology, 1995; 205.
32. Craig WA, Kiem S, Andes D, Ambrose P, Jones R. Impact
of ESBLs on in vivo activity of four cephalosporins in the
neutropenic mouse-thigh infection model [abstract A1318].
In: Interscience Conference of Antimicrobial Agents and
Chemotherapy, Washington DC: American Society for
Microbiology, 2003; 22.
33. Andes D, Craig WA, Bhavnani SM et al. PK-PD evaluation
of doripenem (DOR) against extended spectrum b-lacta-
mase (ESBL) producing Enterobacteraceae [abstract]. In:
41st Infectious Diseases Society of America. Washington DC:
American Society for Microbiology, 2003; 25.
Andes and Craig Treatment of infections with ESBL-producing organisms 17
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11 (Suppl. 6), 10–17
